Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind, Active Placebo-Controlled Pilot Study of MDMA-assisted Psychotherapy in People With Chronic PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with chronic PTSD with a duration of 6 months or longer.~* Have a CAPS score showing moderate to severe symptoms.~* Had at least one unsuccessful attempt at treatment for PTSD, either with talk therapy or with drugs, or stopped treatment because of inability to tolerate psychotherapy or drug therapy.~* Are at least 18 years old.~* Generally healthy.~* Must sign a medical release for the investigators to communicate directly with their therapist and doctors.~* Are willing to refrain from taking any psychiatric medications during the study period.~* Agree that, one week before the MDMA session, will refrain from taking all below unless with prior approval of research team: herbal supplements, nonprescription medications (with the exception of nonsteroidal anti-inflammatory drugs or acetaminophen, any prescription medications, with the exception of birth control pills, thyroid hormone, or other medications;~* Are willing to follow restrictions and guidelines concerning consumption of food, beverages. and nicotine the night before and just prior to each experimental session.~* Are willing to remain overnight at the study site.~* Are willing to be contacted via telephone for all necessary telephone contacts.~* Must have a negative pregnancy test if able to bear children, and agree to use an effective form of birth control.~* Agree not to participate in any other clinical trial for the duration of this clinical trial, including the follow-up period.~* Are proficient in speaking and reading Hebrew.~* Agree to have all psychotherapy sessions recorded to audio/video.~Exclusion Criteria:~* Are pregnant or nursing, or if they can have children and are not practicing an effective means of birth control.~* Weigh less than 48 kg.~* Are abusing illegal drugs.~* Are unable to give adequate informed consent.~* Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary.~* Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lead in: 125 mg MDMA (Open Label) (Type: EXPERIMENTAL): Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
- Active placebo dose MDMA (25 mg) (Type: PLACEBO_COMPARATOR): Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
- Full dose MDMA (125 mg) (Type: EXPERIMENTAL): Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).